Given the high variation in affordability and lower prices of branded generics, it creates economic incentives for physicians and patients (and payors in limited cases) to shift volume from innovator brands to generics.
The resulting rapid decline in a brand's volume and market share is the primary concern of brands facing loss of exclusivity (LoEs). While some degree of branded volume erosion due to generics seems inevitable, the extent of a brand's decline can be mitigated through strategic initiatives.
Our latest white paper explores several strategic options available to innovator companies as they prepare for upcoming LoEs and generic competition in the Indian market. An important consideration while designing an LoE strategy is to understand the impact of the LoE on evolving market dynamics. Download the complete report to learn more.